A quarter-​​century after the U.S. Food and Drug Admin­is­tra­tion approved the first pre­scrip­tion drugs based on the main psy­choac­tive ingre­dient in mar­i­juana, addi­tional med­i­cines derived from or inspired by the cannabis plant itself could soon be making their way to phar­macy shelves, according to drug com­pa­nies, small biotech firms and uni­ver­sity scientists.

Read the article at USA Today →